AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22989372 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated high‐dose bronchial allergen challenges
Number of subjects: 27
Study 19889690 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 71
Study 19889690 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 71
Study 17972537 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine stimulated tilt test (A‐HUT)
Number of subjects: 41
Study 17972537 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerine stimulated tilt test (NTG‐HUT)
Number of subjects: 41
Study 15919301 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative saphenous vein duplex ultrasound scanning
Number of subjects: 58
Study 11943949 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg/day, orally, 5 days/week)
Number of subjects: 55
Study 11943949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 11943949 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 55
Study 11943949 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine and Placebo
Number of subjects: 55
Study 9813932 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-inch paper spacer
Number of subjects: 134
Study 9813932 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-inch paper spacer
Number of subjects: 134
Study 9813932 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-inch paper spacer
Number of subjects: 134
Study 9813932 — intervention group
Group type: EXPERIMENTAL
Intervention: standard 750 ml volumatic spacer
Number of subjects: 134
Study 8137628 — intervention group
Group type: EXPERIMENTAL
Intervention: 200mg RU 486 followed by 5mg 9-methylene-PGE2 gel
Number of subjects: 0
Study 8137628 — intervention group
Group type: EXPERIMENTAL
Intervention: 600mg RU 486 with 3mg or 5mg 9-methylene-PGE2 gel
Number of subjects: 0
Study 8137628 — intervention group
Group type: EXPERIMENTAL
Intervention: 200mg RU 486 followed by 3mg 9-methylene-PGE2 gel
Number of subjects: 0
Study 8137628 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment schedules
Number of subjects: 0
Study 2573300 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 11
Study 2573300 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg
Number of subjects: 11
Study 2573300 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 180 mg
Number of subjects: 11
Study 2573300 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (all doses)
Number of subjects: 11
Study 2573300 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (active drug)
Number of subjects: 11
Study 29719278 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam (n=41)
Number of subjects: 193
Study 29719278 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (n=31)
Number of subjects: 193
Study 29719278 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (n=96)
Number of subjects: 193
Study 29719278 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (n=25)
Number of subjects: 193
Study 29719278 — intervention group
Group type: EXPERIMENTAL
Intervention: AED Starts considered clinically beneficial
Number of subjects: 193
Study 29719278 — intervention group
Group type: COMPARATOR
Intervention: AED Starts not clinically beneficial
Number of subjects: 193
Study 29719278 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically beneficial AED Starts
Number of subjects: 193
Study 26507526 — intervention group
Group type: COMPARATOR
Intervention: IV TXA alone
Number of subjects: 119
Study 26507526 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined IV and topical TXA
Number of subjects: 119
Study 25625130 — intervention group
Group type: EXPERIMENTAL
Intervention: OFL (Optibond FL)
Number of subjects: 35
Study 25625130 — intervention group
Group type: EXPERIMENTAL
Intervention: OSP (Optibond Solo Plus)
Number of subjects: 35
Study 25625130 — intervention group
Group type: EXPERIMENTAL
Intervention: XTR (Optibond XTR)
Number of subjects: 35
Study 25625130 — intervention group
Group type: EXPERIMENTAL
Intervention: AIO (Optibond All-In-One)
Number of subjects: 35
Study 23340559 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine supplementation (twice daily)
Number of subjects: 0
Study 23340559 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 0
Study 20857137 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training on a cycle-ergometer three times per week for 45 min at 70% of VO(2 peak) for 12 weeks
Number of subjects: 14
Study 20857137 — intervention group
Group type: COMPARATOR
Intervention: Pre-training τVO(2p)
Number of subjects: 14
Study 20857137 — intervention group
Group type: COMPARATOR
Intervention: Normalized ∆[HHb]/VO(2p) ratio pre-training
Number of subjects: 14
Study 18505181 — intervention group
Group type: EXPERIMENTAL
Intervention: APL 600 mg twice daily
Number of subjects: 147
Study 18505181 — intervention group
Group type: EXPERIMENTAL
Intervention: APL 800 mg twice daily
Number of subjects: 147
Study 18505181 — intervention group
Group type: COMPARATOR
Intervention: EFV (efavirenz)
Number of subjects: 147
Study 16553341 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (45 patients)
Number of subjects: 90
Study 16553341 — intervention group
Group type: COMPARATOR
Intervention: Propofol (45 patients)
Number of subjects: 90
Study 12776984 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 0
Study 11199313 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (1.8 m2, 220 ml)
Number of subjects: 60
Study 11199313 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (2.5 m2, 270 ml)
Number of subjects: 60
Study 11199313 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (2.2 m2, 290 ml)
Number of subjects: 60
Study 11199313 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 9700445 — intervention group
Group type: EXPERIMENTAL
Intervention: One of six different therapies
Number of subjects: 12
Study 9700445 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemons and oranges
Number of subjects: 12
Study 7871449 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg ciprofloxacin
Number of subjects: 1180
Study 7871449 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg ciprofloxacin
Number of subjects: 1180
Study 7871449 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone, ampicillin/probenecid, amoxicillin/probenecid, spectinomycin
Number of subjects: 1180
Study 3277008 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 3837
Study 3277008 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory ECG monitoring (various durations)
Number of subjects: 3837
Study 3277008 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory ECG monitoring (24 hours)
Number of subjects: 3837
Study 31904566 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination (bivalent)
Number of subjects: 7372
Study 30939198 — intervention group
Group type: EXPERIMENTAL
Intervention: iMVCquad-HHD (fixed handheld dynamometer)
Number of subjects: 65
Study 29129443 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab (15 mg/kg intravenously every 21 days for 1 year)
Number of subjects: 1501
Study 29129443 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 1501
Study 29129443 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab
Number of subjects: 1501
Study 26852501 — intervention group
Group type: EXPERIMENTAL
Intervention: Resonance-microwave therapy with the Akvaton-02 apparatus
Number of subjects: 50
Study 26852501 — intervention group
Group type: COMPARATOR
Intervention: Basic drug therapy
Number of subjects: 50
Study 26852501 — intervention group
Group type: EXPERIMENTAL
Intervention: Resonance-microwave therapy
Number of subjects: 50
Study 23985435 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 1.5% arginine and 1450 ppm fluoride
Number of subjects: 438
Study 23985435 — intervention group
Group type: COMPARATOR
Intervention: Positive control dentifrice containing 1450 ppm fluoride
Number of subjects: 438
Study 23985435 — intervention group
Group type: COMPARATOR
Intervention: Negative control dentifrice without arginine and fluoride
Number of subjects: 438
Study 21483892 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio‐Oss Collagen augmentation
Number of subjects: 25
Study 21483892 — intervention group
Group type: COMPARATOR
Intervention: Unaugmented extraction sockets
Number of subjects: 25
Study 18328638 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 461
Study 18328638 — intervention group
Group type: COMPARATOR
Intervention: Drug Counseling-as-usual
Number of subjects: 461
Study 16907900 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (0.5 mg, t.d.s for 7 days)
Number of subjects: 13
Study 16907900 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 5)
Number of subjects: 13
Study 12737754 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil
Number of subjects: 30000
Study 12737754 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 30000
Study 10669281 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 0.5 mg/kg i.m.
Number of subjects: 109
Study 10669281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 9055768 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound examination
Number of subjects: 240
Study 9055768 — intervention group
Group type: COMPARATOR
Intervention: Initial chest radiograph
Number of subjects: 240
Study 30125891 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized training (department-specific orientation video, locally made posters, and didactic sessions)
Number of subjects: 244
Study 30125891 — intervention group
Group type: COMPARATOR
Intervention: Standard training (videos, posters, and didactic sessions from the World Health Organization)
Number of subjects: 244
Study 30125891 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized training
Number of subjects: 244
Study 30125891 — intervention group
Group type: COMPARATOR
Intervention: Standard training
Number of subjects: 244
Study 26970957 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance and Endurance exercise After ChemoTherapy (REACT)
Number of subjects: 574
Study 26970957 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and Nutrition Routine Improving Cancer Health (ENRICH)
Number of subjects: 574
Study 26970957 — intervention group
Group type: EXPERIMENTAL
Intervention: Move More for Life (MM4L)
Number of subjects: 574
Study 24581015 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Patient Simulation (HPS) education
Number of subjects: 30
Study 24581015 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HPS education)
Number of subjects: 30
Study 22707519 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 186
Study 22707519 — intervention group
Group type: COMPARATOR
Intervention: Usual care by general practitioner
Number of subjects: 186
Study 19595042 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior decompression methods (discectomy of one to three segments, subtotal vertebrectomy of one to two segments, discectomy plus subtotal vertebrectomy)
Number of subjects: 263
Study 19595042 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior decompression methods (posterior expansive single open door laminoplasty and other operation types)
Number of subjects: 263
Study 19595042 — intervention group
Group type: COMPARATOR
Intervention: Age groups and course groups
Number of subjects: 263
Study 16785738 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone alone (1 mg/kg BW/day)
Number of subjects: 51
Study 16785738 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of prednisolone (0.5 mg/kg BW/day) with azathioprine (2 mg/kg BW/day) or cyclosporine (3 mg/kg BW/day)
Number of subjects: 51
Study 16785738 — intervention group
Group type: COMPARATOR
Intervention: No immunosuppressive drugs (Control group)
Number of subjects: 51
Study 16785738 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone alone
Number of subjects: 51
Study 16785738 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of lower prednisolone dose with azathioprine and cyclosporin
Number of subjects: 51
Study 16785738 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treated group
Number of subjects: 51
Study 16785738 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 51
Study 14718058 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide bleaching gel for 8 hours per day for 1 week (Group 2)
Number of subjects: 48
Study 14718058 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sodium ascorbate treatment (Group 3)
Number of subjects: 48
Study 14718058 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion in artificial saliva for 1 week before restoration (Group 4)
Number of subjects: 48
Study 14718058 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching adhesive system and resin composite restoration (Group 1)
Number of subjects: 48
Study 11723415 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone‐acetate (MPA) (10 mg/day) with continuous transdermal estradiol (TE) (50 microg/day)
Number of subjects: 40
Study 11723415 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal danazol (200 mg/day) with continuous TE
Number of subjects: 40
Study 11723415 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen alone (TE)
Number of subjects: 40
Study 11723415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11723415 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (1, 2, 3)
Number of subjects: 40
Study 9469532 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal inflammation induced by cold air (145 ml/s) with varying humidity and temperature
Number of subjects: 20
Study 9469532 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaseous CO2 applied to the left nostril (36 stimuli of 200 ms; 65% v/v CO2; interstimulus interval 30 s)
Number of subjects: 20
Study 8188800 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on clue words
Number of subjects: 0
Study 8188800 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 3540139 — intervention group
Group type: EXPERIMENTAL
Intervention: B subunit‐killed whole cell (BS‐WC) cholera vaccine
Number of subjects: 1257
Study 3540139 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed whole cell‐only (WC) cholera vaccine
Number of subjects: 1257
Study 3540139 — intervention group
Group type: COMPARATOR
Intervention: Killed Escherichia coli strain K12 placebo
Number of subjects: 1257
Study 3540139 — intervention group
Group type: COMPARATOR
Intervention: Control agent
Number of subjects: 1257
Study 29232316 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIME
Number of subjects: 107
Study 29232316 — intervention group
Group type: COMPARATOR
Intervention: AT
Number of subjects: 107
Study 27939054 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRP-T vaccine co-administered with MenC vaccine (Group 1; n=175)
Number of subjects: 350
Study 27939054 — intervention group
Group type: COMPARATOR
Intervention: DTaP-IPV-HB-PRP-T vaccine without MenC vaccine (Group 2; n=175)
Number of subjects: 350
Study 25677790 — intervention group
Group type: COMPARATOR
Intervention: Protocol A: Conventional 120-kVp protocol with standard CM dose (280 mg iodine/kg body weight)
Number of subjects: 90
Study 25677790 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol B: 80-kVp with 25% CM dose reduction (210 mg iodine/kg body weight)
Number of subjects: 90
Study 25677790 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol C: 80-kVp with 50% CM dose reduction (140 mg iodine/kg body weight)
Number of subjects: 90
Study 23127806 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG)
Number of subjects: 138
Study 23127806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 21440942 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 or 4 mg intravitreal triamcinolone
Number of subjects: 209
Study 21440942 — intervention group
Group type: COMPARATOR
Intervention: Standard care (observation or grid photocoagulation)
Number of subjects: 209
Study 19004201 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiweikang Capsule
Number of subjects: 67
Study 19004201 — intervention group
Group type: COMPARATOR
Intervention: Wenweishu Capsule
Number of subjects: 67
Study 17154645 — intervention group
Group type: COMPARATOR
Intervention: RIX4414 (Rotarix™)
Number of subjects: 63225
Study 15134313 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Management Training (PMT)
Number of subjects: 238
Study 10891016 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention program (avoidance of house dust mite and pet allergens, environmental tobacco smoke, encouragement of breastfeeding, supplementation with partially hydrolyzed formula)
Number of subjects: 545
Study 10891016 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 545
Study 10891016 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention program
Number of subjects: 545
Study 10891016 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 545
Study 9291901 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronotherapy
Number of subjects: 186
Study 9291901 — intervention group
Group type: COMPARATOR
Intervention: Constant-rate infusion
Number of subjects: 186
Study 7508773 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon at 1.5 x 10(6) U three times per week for 1 year
Number of subjects: 88
Study 7508773 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 88
Study 7508773 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 88
Study 3525369 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy plus oral propranolol (dose sufficient to reduce resting pulse rate by 25%)
Number of subjects: 53
Study 3525369 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy alone
Number of subjects: 53
Study 31294749 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg/kg every 3 weeks) after 3 doses of 8 Gy stereotactic body radiotherapy
Number of subjects: 92
Study 31294749 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab (200 mg/kg every 3 weeks) alone (control arm)
Number of subjects: 92
Study 28580293 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 100
Study 28580293 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 100
Study 28580293 — intervention group
Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 100
Study 28580293 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 100
Study 25822236 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster Plus (ABP visible during training and testing)
Number of subjects: 36
Study 25822236 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster Alone (ABP visible only during training, not testing)
Number of subjects: 36
Study 25822236 — intervention group
Group type: COMPARATOR
Intervention: Control (testing, no intervention)
Number of subjects: 36
Study 23434449 — intervention group
Group type: EXPERIMENTAL
Intervention: Penehyclidine hydrochloride (0.05 mg/kg IV 10 minutes before cardiopulmonary bypass)
Number of subjects: 40
Study 23434449 — intervention group
Group type: COMPARATOR
Intervention: Control (saline injection)
Number of subjects: 40
Study 23434449 — intervention group
Group type: EXPERIMENTAL
Intervention: Penehyclidine hydrochloride
Number of subjects: 40
Study 21277510 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Number of subjects: 14
Study 21277510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 19876674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) with varied administration of exposure
Number of subjects: 369
Study 19876674 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 369
Study 16990724 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative motion with a mobile hinge and a motion protocol
Number of subjects: 55
Study 16990724 — intervention group
Group type: COMPARATOR
Intervention: Postoperative nonmotion with a locked hinge
Number of subjects: 55
Study 14734877 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐ORS
Number of subjects: 189
Study 14734877 — intervention group
Group type: COMPARATOR
Intervention: G‐ORS
Number of subjects: 189
Study 11376225 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphically enhanced consent disclosure form
Number of subjects: 241
Study 11376225 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a third-party facilitator
Number of subjects: 241
Study 11376225 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterative feedback during consent process
Number of subjects: 241
Study 11376225 — intervention group
Group type: COMPARATOR
Intervention: Standard dense text consent disclosure form
Number of subjects: 241
Study 11376225 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 241
Study 11376225 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia group
Number of subjects: 241
Study 9207282 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (75 mg, 3 mL intramuscular injection)
Number of subjects: 53
Study 9207282 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 mL saline, intramuscular injection)
Number of subjects: 53
Study 8272262 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-1 ganglioside, administered intravenously at a dose of 100 mg, 6 days a week for 2 months
Number of subjects: 0
Study 8272262 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-1 ganglioside
Number of subjects: 0
Study 8272262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3619096 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine plus 1 ml normal saline (Group 1)
Number of subjects: 96
Study 3619096 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus 0.2 mg epinephrine (Group 3)
Number of subjects: 96